HLA-C and acute myeloid leukemia: Flotetuzumab, a CD123xCD3‐targeting dual affinity retargeting antibody that works by enhancing the formation of an immunologic synapse between cytotoxic T‐ and AML cells independent of the major histocompatibility complex (MHC) pathway, has shown promising efficacy in TP53mut (complete remission 47%, median survival 10.3 months) [150].